However, while IgE levels are not typically used for guiding anti-IL5/5Rα therapy, it is noteworthy that benralizumab was able to reduce total IgE levels correlated with a reduction in basophils (but not eosinophiles) and with an improvement in asthma control [176]. The gene discussed is IL5; the disease is asthma.